Unlock instant, AI-driven research and patent intelligence for your innovation.

A method for preparing non-peptide selective vasopressin antagonist

An inert solvent, selected technology, applied in the field of preparation of tolvaptan, a selective non-peptidin arginine vasopressin V2 receptor antagonist, can solve problems such as difficulties in the preparation of analogues

Active Publication Date: 2020-07-03
上海天慈中商药业有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] Route five is the synthetic method reported by Alejandro Cordero-Vargas et al. in Bioorg.Med.Chem., 2006,14(18):6165-6173, wherein, 7-chloro-5-oxo-2,3,4,5 -Tetrahydro-1H-1-benzazepine The preparation of analogues is more difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for preparing non-peptide selective vasopressin antagonist
  • A method for preparing non-peptide selective vasopressin antagonist
  • A method for preparing non-peptide selective vasopressin antagonist

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0143] The preparation method of described formula (IV) compound comprises steps:

[0144] (1) In an inert solvent, react the compound of formula (II) with the compound of formula (III) to obtain the compound of formula (IV);

[0145]

[0146] The step (1) is preferably carried out in the presence of a base catalyst. The base is not particularly limited, and may be an organic base and / or an inorganic base commonly used in the art; preferably, the organic base is selected from the group consisting of triethylamine, pyridine, diisopropylethylamine, N-methylmorpholine, DBU, or a combination thereof; the inorganic base is selected from the group consisting of sodium carbonate, sodium bicarbonate, potassium carbonate, cesium carbonate, or a combination thereof.

[0147] The solvent is not particularly limited, preferably a solvent selected from the group consisting of dichloromethane, acetonitrile, tetrahydrofuran, 1,4-dioxane, toluene, xylene, or a combination thereof.

[014...

Embodiment 1

[0223] (1) Synthesis of Compound (Ⅳ)

[0224]Dissolve p-chloroaniline (41.0g, 321.39mmol) in dichloromethane (600mL), add triethylamine (65.04g, 642.78mmol), stir for 15min, then slowly add 4-nitro-2-methyl Benzoyl chloride (76.98g, 385.67mmol) was reacted at room temperature for 1h, and the reaction was completed by TLC detection. Pour the reaction solution into water (300mL), wash the organic phase water with water (100mL) and brine (100mL) successively, dry over anhydrous sodium sulfate, and spin off dichloromethane to obtain the product compound (Ⅳ) (82.22g, 88%) .

[0225] 1 H-NMR(400MHz,DMSO):δ8.33(s,1H),8.29(s,1H),8.18(s,1H),7.78~7.74(m,2H),7.49~7.45(m,2H), 2.48(s,3H). C 14 h 11 ClN 2 o 3 (M+H) + Calcd: 290.0458, found: 290.0455.

[0226] (2) Synthesis of compound (Ⅵ)

[0227] Compound (Ⅳ) (40.0g, 137.60mmol) was dispersed in acetonitrile (300mL), and ethyl 4-bromobutyrate (Ⅴ) (29.52g, 151.36mmol) and anhydrous sodium carbonate (29.17g, 275.20mmol) were added...

Embodiment 2

[0241] (1) Synthesis of Compound (Ⅳ)

[0242] Dissolve p-chloroaniline (40.0g, 313.55mmol) in dichloromethane (600mL), add diisopropylethylamine (81.05g, 627.10mmol), stir for 15min, and then slowly add 4-nitro-2 -Methylbenzoyl chloride (75.10g, 376.26mmol), reacted at room temperature for 1h, detected by TLC, the reaction was complete. Pour the reaction solution into water (300mL), wash the organic phase water with water (100mL) and brine (100mL) successively, dry over anhydrous sodium sulfate, and spin off dichloromethane to obtain the product compound (Ⅳ) (82.49g, 90.5%) .

[0243] (2) Synthesis of compound (Ⅵ)

[0244] Compound (Ⅳ) (40.0g, 137.60mmol) was dispersed in acetonitrile (300mL), and ethyl 4-bromobutyrate (Ⅴ) (29.52g, 151.36mmol) and anhydrous potassium carbonate (38.04g, 275.20mmol) were added , stirring and heating to reflux for 4.5h, TLC detection, the reaction was complete. Pour the reaction solution into water (100mL), spin off THF, extract with dichloro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a method for preparing a non-peptide antagonist of selective vasopressin. Specifically, the invention provides a compound shown as the formula A, and a method for preparing tolvaptan through the compound shown as the formula A. The method has advantages of environmental protection, available raw materials, and high total yield, and is suitable for industrial preparation of tolvaptan.

Description

technical field [0001] The invention belongs to the technical field of chemical pharmacy and relates to a selective non-peptidin arginine vasopressin (AVP) V 2 A method for preparing tolvaptan as a receptor antagonist. Background technique [0002] The English name of tolvaptan is Tolvaptan, and the trade name is Samsca. This drug is a selective vasopressin V 2 Receptor antagonists that prevent AVP from interacting with V in distal nephrons 2 Receptor binding increases water excretion in urine, but does not change urinary sodium and potassium secretion and blood potassium value, reduces urine osmotic pressure, and increases blood sodium value, so it is clinically used to treat liver cirrhosis, heart failure, Hypervolemic and isovolemic hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH). The drug is well tolerated, does not disrupt electrolyte balance, and has mild adverse reactions. Tolvaptan was approved by the US FDA in 2009 as an ora...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07C233/83C07C231/12C07C231/02C07D223/16C07C233/66
Inventor 李新涓子李健之马西来池王胄刘海胡旭华郑肖利翟志军李建勋
Owner 上海天慈中商药业有限公司